Shanghai Henlius Biotech Inc. Held Extraordinary General Meeting
I'm PortAI, I can summarize articles.
Shanghai Henlius Biotech Inc. held its fourth extraordinary general meeting on December 31, 2025, where shareholders approved the Sinopharm Distribution Framework Agreement (2025 Renewal) and related transactions, including annual caps. This information was published via the Issuer Information Service by the Hong Kong Stock Exchange.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments